RxDoctor Payments Data

Kelly Casperson, MD

Urology · Bellingham, WANPI 1992828743

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by AbbVie at 50.5% of the total. Reporting peaked in 2021 at $10,219 and has fallen 99.4% since, to $58 in 2025. Among urology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,409in general payments, 2019–2025

Across 406 payments — averaging $65.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Medtronic$6K
  • Axonics, Inc.$3K
  • Neotract Inc.$659
  • Astellas Pharma US Inc$624
  • Johnson & Johnson$429
  • plus $3K from 41 others

What the payments were for

  • Consulting fees$1,1004%
  • Speaking & faculty fees$14,71456%
  • Travel & lodging$3,03411%
  • Food & beverage$7,02527%
  • Education$5362%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,409 in reported general payments places this provider in the 90th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$142,937
Medicare patients
464
Services billed
1,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$153,032
MyrbetriqMirabegron41$31,388
Estradiol257$14,610
GemtesaVibegron29$13,664
EstringEstradiol19$10,287
Tamsulosin Hcl145$3,206
Methenamine Hippurate37$2,448
Potassium Citrate ErPotassium Citrate23$1,623
Estradiol (Twice Weekly)Estradiol13$1,144
Oxybutynin Chloride ErOxybutynin Chloride44$700
NitrofurantoinNitrofurantoin Macrocrystal17$495
ProgesteroneProgesterone, Micronized14$448
Finasteride19$344
Ciprofloxacin Hcl203$233
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim50$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$624$184,42152 claims
Sumitomo Pharma America, Inc.Gemtesa$189$13,66429 claims
PfizerEstring$199$10,28719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 274 urology providers in Washington.

Other urology in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →